Laser capture microdissection is a valuable tool in the preoperative molecular screening of follicular lesions of the thyroid: An institutional experience

Cytopathology

Volumn 26, Issue 5, 2015, Pages 288-296

  Bongiovanni, M ^a   Molinari, F ^a   Eszlinger, M ^b   Paschke, R ^b   Barizzi, J ^a   Merlo, E ^a   Giovanella, L ^c   Fasolini, F ^d   Cattaneo, F ^e   Ramelli, F ^f   Mazzucchelli, L ^a   Frattini, M ^a  

^a INSTITUTE OF PATHOLOGY   (Switzerland)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^d REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^e Private Practice Endocrinologist   (Switzerland)

^f Private Practice   (Switzerland)

Author keywords

BRAF; RAS; Fine needle aspiration; Laser capture microdissection; Molecular analysis; PAX8 PPARG; RET PTC; Thyroid follicular lesions

Indexed keywords

B RAF KINASE; COMPLEMENTARY DNA; DNA; RAS PROTEIN; RNA; TRANSCRIPTION FACTOR PAX8; BRAF PROTEIN, HUMAN; PAIRED BOX TRANSCRIPTION FACTOR; PAX8 PROTEIN, HUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN RET; RET PROTEIN, HUMAN;

ARTICLE; CANCER CYTODIAGNOSIS; DNA EXTRACTION; FINE NEEDLE ASPIRATION BIOPSY; FOLLICULAR CARCINOMA; GENE MUTATION; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MOLECULAR DIAGNOSIS; NODULAR HYPERPLASIA; ONCOGENE H RAS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; THYROID CANCER; THYROID FOLLICULAR ADENOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID PARAFOLLICULAR CELL CARCINOMA; TISSUE SECTION; ADENOCARCINOMA, FOLLICULAR; ADENOMA; CYTODIAGNOSIS; FEMALE; GENETICS; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; THYROID GLAND; THYROID NEOPLASMS;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; BIOPSY, FINE-NEEDLE; CYTODIAGNOSIS; DNA; FEMALE; HUMANS; LASER CAPTURE MICRODISSECTION; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; PAIRED BOX TRANSCRIPTION FACTORS; PPAR GAMMA; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; RAS PROTEINS; RETROSPECTIVE STUDIES; RNA; THYROID GLAND; THYROID NEOPLASMS;

EID: 84942113552     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/cyt.12226     Document Type: Article

References (53)

1. De Lellis RA, Williams ED. Thyroid and parathyroid tumours: introduction. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumors of Endocrine Organs. DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds). Lyon: IARC Press; 2004: pp. 51-6.
2. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993;328:553-9.
3. Gharib H, Papini E, Valcavi R et al. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 2006;12:63-102.
4. Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.
5. Bukhari MH, Niazi S, Hanif G et al. An updated audit of fine needle aspiration cytology procedure of solitary thyroid nodule. Diagn Cytopathol 2008;36:104-12.
6. Werga P, Wallin G, Skoog L, Hamberger B. Expanding role of fine-needle aspiration cytology in thyroid diagnosis and management. World J Surg 2000;24:907-12.
7. Baloch ZW, Fleisher S, LiVolsi VA, Gupta PK. Diagnosis of "follicular neoplasm": a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol 2002;26:41-4.
8. Ali SZ, Cibas ES. The Bethesda System for Reporting Thyroid Cytopathology. Definitions, Criteria and Explanatory Notes. New York: Springer; 2010.
9. Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis. Acta Cytol 2012;56:333-9.
10. Nikiforov YE, Ohori NP, Hodak SP et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011;96:3390-7.
11. Elsheikh TM, Rossi ED. Utilization of molecular testing in thyroid cytology. Pathol Case Rev 2014;19:3-7.
12. Yip L, Farris C, Kabaker AS et al. Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J Clin Endocrinol Metab 2012;97:1905-12.
13. Ferraz C, Rehfeld C, Krogdahl A et al. Detection of PAX8/PPARG and RET/PTC rearrangements is feasible in routine air-dried fine needle aspiration smears. Thyroid 2012;22:1025-30.
14. Eszlinger M, Krogdahl A, Muenz S et al. Impact of molecular screening for point mutations and rearrangements in routine air-dried fine needle aspiration samples of thyroid nodules. Thyroid 2014;24:305-13.
15. Ferraz C, Eszlinger M, Paschke R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab 2011;96:2016-26.
16. Nikiforov YE, Yip L, Nikiforova MN. New strategies in diagnosing cancer in thyroid nodules: impact of molecular markers. Clin Cancer Res 2013;19:2283-8.
17. Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab 2013;98:E1852-60.
18. Walsh PS, Wilde JI, Tom EY et al. Analytical performance verification of a molecular diagnostic for cytology-indeterminate thyroid nodules. J Clin Endocrinol Metab 2012;97:E2297-306.
19. Melillo RM, Santoro M. Molecular biomarkers in thyroid FNA samples. J Clin Endocrinol Metab 2012;97:4370-3.
20. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011;7:569-80.
21. Nikiforov YE, Steward DL, Robinson-Smith TM et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009;94:2092-8.
22. Niyaz Y, Stich M, Sagmuller B et al. Noncontact laser microdissection and pressure catapulting: sample preparation for genomic, transcriptomic, and proteomic analysis. Methods Mol Med 2005;114:1-24.
23. Vandewoestyne M, Goossens K, Burvenich C et al. Laser capture microdissection: should an ultraviolet or infrared laser be used? Anal Biochem 2013;439:88-98.
24. Frattini M, Ferrario C, Bressan P et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004;23:7436-40.
25. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12.
26. Frattini M, Saletti P, Romagnani E et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007;97:1139-45.
27. Algeciras-Schimnich A, Milosevic D, McIver B et al. Evaluation of the PAX8/PPARG translocation in follicular thyroid cancer with a 4-color reverse-transcription PCR assay and automated high-resolution fragment analysis. Clin Chem 2010;56:391-8.
28. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-7.
29. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013;381:1058-69.
30. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 1997;57:1690-4.
31. Rabes HM, Demidchik EP, Sidorow JD et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res 2000;6:1093-103.
32. Bounacer A, Wicker R, Caillou B et al. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 1997;15:1263-73.
33. Handkiewicz-Junak D, Czarniecka A, Jarzab B. Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Mol Cell Endocrinol 2010;322:8-28.
34. Howell GM, Hodak SP, Yip L. RAS mutations in thyroid cancer. Oncologist 2013;18:926-32.
35. Schulten HJ, Salama S, Al-Ahmadi A et al. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population. Anticancer Res 2013;33:4779-84.
36. Cantara S, Capezzone M, Marchisotta S et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab 2010;95:1365-9.
37. Moses W, Weng J, Sansano I et al. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J Surg 2010;34:2589-94.
38. Pacini F, Cantara S, Capezzone M. Search for genetic mutations in cytological samples from thyroid nodules as a diagnostic tool: reality, hope or myth? J Endocrinol Invest 2010;33:576-8.
39. Ohori NP, Nikiforova MN, Schoedel KE et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathol 2010;118:17-23.
40. Dejmek A, Zendehrokh N, Tomaszewska M, Edsjö A. Preparation of DNA from cytological material: effects of fixation, staining, and mounting medium on DNA yield and quality. Cancer Cytopathol 2013;121:344-53.
41. Fischer AH, Benedict CC, Amrikachi M. Five top stories in cytopathology. Arch Pathol Lab Med 2013;137:894-906.
42. Poller DN, Glaysher S. BRAF V600 co-testing is technically feasible in conventional thyroid fine needle aspiration (FNA) cytology smears and can reduce the need for completion thyroidectomy. Cytopathology 2014;25:155-9.
43. Johnson SJ, Hardy SA, Roberts C et al. Pilot of BRAF mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology. Cytopathology 2014;25:146-54.
44. Khode R, Larsen DA, Culbreath BC et al. Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas. Cancer Cytopathol 2013;121:361-9.
45. Mitiushkina NV, Iyevleva AG, Poltoratskiy AN et al. Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides. Cancer Cytopathol 2013;121:370-6.
46. Malapelle U, Bellevicine C, De Luca C et al. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients. Cancer Cytopathol 2013;121:552-60.
47. Smits AJ, Kummer JA, de Bruin PC et al. The estimation of tumor cell percentage for molecular testing by pathologists is not accurate. Mod Pathol 2014;27:168-74.
48. Marchetti I, Iervasi G, Mazzanti CM et al. Detection of the BRAF(V600E) mutation in fine needle aspiration cytology of thyroid papillary microcarcinoma cells selected by manual macrodissection: an easy tool to improve the preoperative diagnosis. Thyroid 2012;22:292-8.
49. Dogan S, Becker JC, Rekhtman N et al. Use of touch imprint cytology as a simple method to enrich tumor cells for molecular analysis. Cancer Cytopathol 2013;121:354-60.
50. Simone NL, Bonner RF, Gillespie JW, Emmert-Buck MR, Liotta LA. Laser-capture microdissection: opening the microscopic frontier to molecular analysis. Trends Genet 1998;14:272-6.
51. Bonner RF, Emmert-Buck M, Cole K et al. Laser capture microdissection: molecular analysis of tissue. Science 1997;278:1481-3.
52. da Cunha Santos G. Standardizing preanalytical variables for molecular cytopathology. Cancer Cytopathol 2013;121:341-3.
53. Le Mercier M, D'Haene N, De Neve N et al. Next-generation sequencing improves the diagnosis of thyroid FNA specimens with indeterminate cytology. Histopathology 2014 May 17. doi: 10.1111/his.12461. [Epub ahead of print]